An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds.

Simpraga S, Mansvelder HD, Groeneveld GJ, Prins S, Hart EP, Poil SS, Linkenkaer-Hansen K

Cognitive impairment models are used in clinical studies aimed at proving pharmacology of drugs being developed for Alzheimer's disease and other cognitive disorders. Due to rising interest in nicotinic agonists, we aimed to establish a method to monitor neurophysiological effects of modulating the nicotinic cholinergic system.